JP2020096630A5 - - Google Patents

Download PDF

Info

Publication number
JP2020096630A5
JP2020096630A5 JP2020025935A JP2020025935A JP2020096630A5 JP 2020096630 A5 JP2020096630 A5 JP 2020096630A5 JP 2020025935 A JP2020025935 A JP 2020025935A JP 2020025935 A JP2020025935 A JP 2020025935A JP 2020096630 A5 JP2020096630 A5 JP 2020096630A5
Authority
JP
Japan
Prior art keywords
nucleic acid
cldn6
recombinant nucleic
cell
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020025935A
Other languages
English (en)
Japanese (ja)
Other versions
JP6985440B2 (ja
JP2020096630A (ja
Filing date
Publication date
Priority claimed from JP2017503063A external-priority patent/JP6726656B2/ja
Application filed filed Critical
Publication of JP2020096630A publication Critical patent/JP2020096630A/ja
Publication of JP2020096630A5 publication Critical patent/JP2020096630A5/ja
Priority to JP2021190855A priority Critical patent/JP7451858B2/ja
Application granted granted Critical
Publication of JP6985440B2 publication Critical patent/JP6985440B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020025935A 2014-04-01 2020-02-19 クローディン6特異的免疫受容体およびt細胞エピトープ Active JP6985440B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021190855A JP7451858B2 (ja) 2014-04-01 2021-11-25 クローディン6特異的免疫受容体およびt細胞エピトープ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2014/000868 2014-04-01
EP2014000868 2014-04-01
EP2014072864 2014-10-24
EPPCT/EP2014/072864 2014-10-24
JP2017503063A JP6726656B2 (ja) 2014-04-01 2015-03-30 クローディン6特異的免疫受容体およびt細胞エピトープ

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017503063A Division JP6726656B2 (ja) 2014-04-01 2015-03-30 クローディン6特異的免疫受容体およびt細胞エピトープ

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021190855A Division JP7451858B2 (ja) 2014-04-01 2021-11-25 クローディン6特異的免疫受容体およびt細胞エピトープ

Publications (3)

Publication Number Publication Date
JP2020096630A JP2020096630A (ja) 2020-06-25
JP2020096630A5 true JP2020096630A5 (cg-RX-API-DMAC7.html) 2020-08-06
JP6985440B2 JP6985440B2 (ja) 2021-12-22

Family

ID=52745896

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017503063A Active JP6726656B2 (ja) 2014-04-01 2015-03-30 クローディン6特異的免疫受容体およびt細胞エピトープ
JP2020025935A Active JP6985440B2 (ja) 2014-04-01 2020-02-19 クローディン6特異的免疫受容体およびt細胞エピトープ
JP2021190855A Active JP7451858B2 (ja) 2014-04-01 2021-11-25 クローディン6特異的免疫受容体およびt細胞エピトープ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017503063A Active JP6726656B2 (ja) 2014-04-01 2015-03-30 クローディン6特異的免疫受容体およびt細胞エピトープ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021190855A Active JP7451858B2 (ja) 2014-04-01 2021-11-25 クローディン6特異的免疫受容体およびt細胞エピトープ

Country Status (21)

Country Link
US (3) US10370423B2 (cg-RX-API-DMAC7.html)
EP (3) EP3708579B1 (cg-RX-API-DMAC7.html)
JP (3) JP6726656B2 (cg-RX-API-DMAC7.html)
CN (3) CN106459165B (cg-RX-API-DMAC7.html)
AU (3) AU2015239683B2 (cg-RX-API-DMAC7.html)
CA (1) CA2942459C (cg-RX-API-DMAC7.html)
CY (1) CY1121539T1 (cg-RX-API-DMAC7.html)
DK (3) DK3514172T3 (cg-RX-API-DMAC7.html)
ES (3) ES2784537T3 (cg-RX-API-DMAC7.html)
FI (1) FI3708579T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20240926T1 (cg-RX-API-DMAC7.html)
HU (3) HUE050355T2 (cg-RX-API-DMAC7.html)
LT (2) LT3708579T (cg-RX-API-DMAC7.html)
ME (1) ME03407B (cg-RX-API-DMAC7.html)
MX (1) MX376026B (cg-RX-API-DMAC7.html)
PL (3) PL3514172T3 (cg-RX-API-DMAC7.html)
PT (3) PT3126381T (cg-RX-API-DMAC7.html)
RS (2) RS58627B2 (cg-RX-API-DMAC7.html)
SI (3) SI3514172T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900262T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015150327A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689911B1 (en) * 2009-11-11 2024-08-21 Astellas Pharma Inc. Antibodies specific for claudin 6 (cldn6)
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
AU2014346792A1 (en) 2013-11-06 2016-06-02 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
EP3218404B1 (en) * 2014-11-14 2021-01-06 The United States of America, as represented by The Secretary, Department of Health and Human Services Human anti-thyroglobulin t cell receptors
CN106146666B (zh) * 2015-03-26 2019-09-06 科济生物医药(上海)有限公司 靶向cldn6的免疫效应细胞及其制备方法和应用
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
MA55153A (fr) 2016-02-19 2021-09-29 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
US12048718B2 (en) 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
BR112019000512A2 (pt) 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
BR112019007100A2 (pt) * 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
AU2018234830B2 (en) * 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
BR112019019941B1 (pt) * 2017-03-27 2023-12-05 Noile-Immune Biotech, Inc Polinucleotídeo compreendendo uma sequência de base que codifica o receptor de antígeno quimérico, vetor e método
KR20250020679A (ko) 2017-08-04 2025-02-11 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
SG11202002114RA (en) * 2017-09-18 2020-04-29 Univ California Claudin6 antibodies and methods of treating cancer
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN113454111A (zh) 2018-11-06 2021-09-28 健玛保 抗体配制剂
JP7558935B2 (ja) * 2018-11-09 2024-10-01 フレッド ハッチンソン キャンサー センター メソテリンを標的とする免疫療法
MX2021006578A (es) * 2018-12-05 2021-07-07 Genentech Inc Procedimientos de diagnostico y composiciones para la inmunoterapia contra el cancer.
ES3074608T3 (es) * 2019-02-08 2026-07-22 Biontech Cell & Gene Therapies Gmbh Células modificadas con receptores quiméricos de antígeno para el tratamiento de cánceres que expresan CLDN6
WO2020180648A1 (en) * 2019-03-01 2020-09-10 Gritstone Oncology, Inc. Selection of t cell receptors
DK3941946T3 (da) 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
WO2021129927A1 (en) * 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
WO2021156326A1 (en) 2020-02-04 2021-08-12 Genmab A/S Antibodies for use in therapy
KR20230107281A (ko) 2020-11-11 2023-07-14 비온테크 에스이 프로그램된 사멸-1 단백질에 대한 모노클로날 항체 및 의약에서의 용도
WO2022147075A1 (en) * 2020-12-30 2022-07-07 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1)
BR112023027006A2 (pt) 2021-06-21 2024-03-12 BioNTech SE Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
CA3230426A1 (en) * 2021-09-03 2023-03-09 Novarock Biotherapeutics, Ltd. Bispecific binding proteins that bind cd137 and a tumor associated antigen
WO2023057534A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination
AU2022360108A1 (en) 2021-10-06 2024-05-02 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
EP4415761A4 (en) * 2021-10-14 2025-12-24 Health Research Inc COMPOSITIONS AND METHODS OF USE OF RECOMBINANT T LYMPHOCYTE RECEPTORS AGAINST CLAUDIN 6
CA3253038A1 (en) 2022-05-12 2023-11-16 Genmab A/S LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY
TW202409090A (zh) 2022-05-12 2024-03-01 丹麥商珍美寶股份有限公司 在組合療法中能夠結合到cd27之結合劑
EP4522654A1 (en) 2022-05-12 2025-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
CN115232207B (zh) * 2022-05-19 2023-06-13 河南大学 抗体-溶菌素(SM-ScFv-Fc-Ly)在治疗变形链球菌感染中的应用
WO2024165057A1 (en) 2023-02-07 2024-08-15 LaNova Medicines Limited Antibodies and antibody-drug conjugates targeting claudin 6
EP4688160A1 (en) 2023-04-06 2026-02-11 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
KR20260015262A (ko) 2023-05-25 2026-02-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 클라우딘-6 접합체의 투여량
CN122249464A (zh) 2023-11-30 2026-06-19 金麦安博股份有限公司 在组合疗法中的能够结合ox40的抗体
WO2025184170A1 (en) 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment
CN119320451B (zh) * 2024-08-21 2025-05-16 百吉生物医药(广州)股份有限公司 一种紧密连接蛋白抗体d03及其应用
CN118812714B (zh) * 2024-08-21 2025-05-27 广州百吉生物制药有限公司 一种紧密连接蛋白抗体b3及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US9078843B2 (en) * 2005-09-22 2015-07-14 Irun R. Cohen Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
WO2008114733A1 (ja) * 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
AU2009203464A1 (en) * 2008-01-11 2009-07-16 Forerunner Pharma Research Co., Ltd. Anti-CLDN6 antibody
MX2011008430A (es) 2009-02-20 2011-09-29 Ganymed Pharmaceuticals Ag Metodos y composiciones para diagnostico y tratamiento del cancer.
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
EP3689911B1 (en) * 2009-11-11 2024-08-21 Astellas Pharma Inc. Antibodies specific for claudin 6 (cldn6)
US8840902B2 (en) * 2010-03-16 2014-09-23 Biontech Ag Tumor vaccination involving a humoral immune response against self-proteins
CA2795643C (en) * 2010-04-13 2018-07-17 Sigma-Aldrich Co. Llc Methods for generating endogenously tagged protein
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3115373B1 (en) * 2010-09-08 2019-08-28 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
FR2970083B1 (fr) 2011-01-05 2013-02-15 Leosphere Procede et dispositif de determination des mouvements d'un fluide a partir de mesures a distance de vitesses radiales.
EP3026064B1 (en) * 2011-05-13 2018-10-17 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer

Similar Documents

Publication Publication Date Title
JP7227290B2 (ja) キメラ抗原受容体、組成物及び方法
US20230241172A1 (en) Interleukin-18 variants and methods of use
KR102223873B1 (ko) 단일 도메인 항체에 기반한 bcma 키메라 항원 수용체 및 응용
CN108715859B (zh) 靶向cd22的嵌合抗原受体及其应用
CN111925451B (zh) 一种靶向bcma的嵌合抗原受体(car)及其应用
KR20180054590A (ko) 항글리피칸-3 항체 및 이의 응용
KR102316091B1 (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
JP7138989B1 (ja) メソテリンに特異的に結合する抗メソテリンキメラ抗原受容体
KR20190133723A (ko) 개선된 항원 결합 수용체
WO2019137518A1 (zh) 以cd19为靶点的特异性抗体、car-nk细胞及其制备方法和应用
CN114409797B (zh) 重组抗体及其应用
CN115466331B (zh) 靶向bcma的嵌合抗原受体及其应用
JP2021533755A (ja) Hla−drに結合するキメラ抗原受容体およびcar−t細胞
US20230357355A1 (en) Cspg4-targeting humanized chimeric antigen receptor, immune effector cell expressing chimeric antigen receptor, and applications thereof
CN116589584A (zh) 靶向人Nectin4蛋白的抗体或其片段和应用
CN110981960B (zh) 一种嵌合抗原受体(car)及其应用
CN116284419A (zh) 靶向人gucy2c蛋白的单克隆抗体及其应用
JP2021536256A (ja) 修飾t細胞に対する条件的活性型キメラ抗原受容体
CN110938148A (zh) 靶向cd19和cd22嵌合抗原受体
CN114685659B (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体
CN114920841B (zh) 抗cd87抗体及其特异性嵌合抗原受体
JP7054143B2 (ja) キメラ抗原受容体、及びその利用
EP4301402A1 (en) Bispecific antibodies enhancing cell mediated immune responses
WO2022150379A1 (en) Nk cell engager molecules and methods of use
WO2026007830A1 (zh) 一种靶向cd7的纳米抗体及其应用